When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

• The Trade: LiveOne, Inc. (NASDAQ: LVO) CEO and Chairman Robert S Ellin acquired a total of 10000 shares at an average price of $2.30. The insider spent $22,959.00 to buy those shares.
• What’s Happening: LiveOne recently reported a media partnership with Empire Media Group for an eight-figure, multi-year deal.
• What LiveOne Does: LiveOne Inc, formerly LiveXLive Media Inc is the premium internet networks devoted to live music and music-related video content.

• The Trade: Recro Pharma, Inc. (NASDAQ: REPH) CEO David Enloe Jr acquired a total of 1725 shares at an average price of $1.68. The insider spent $2,895.24 to buy those shares.
• What’s Happening: The company recently posted upbeat quarterly sales.
• What Recro Pharma Does: Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products.

• The Trade: Live Current Media Inc. (OTC: LIVC) Director Amir Vahabzadeh acquired a total of 173210 shares at an average price of $0.33. To acquire these shares, it cost $56,849.22.
• What’s Happening: Live Current, last month, signed a new marketing agreement with Think Ink Marketing.
• What Live Current Media Does: Live Current Media Inc is a digital technology company involved in the entertainment industry. Currently, the company is developing two projects, SPRT MTRX for App Store and Play Store and Boxing.com FEDERATION.

• The Trade: Cidara Therapeutics, Inc. (NASDAQ: CDTX) President and CEO Jeffrey Stein acquired a total of 50000 shares shares at an average price of $1.59. The insider spent $79,530.00 to buy those shares.
• What’s Happening: Cidara Therapeutics recently posted a Q3 loss of $0.37 per share.
• What Cidara Therapeutics Does: Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases.

• The Trade: ARC Document Solutions, Inc. (NYSE: ARC) Director Mark Mealy acquired a total of 20000 shares shares at an average price of $3.08. The insider spent $61,536.50 to buy those shares.
• What’s Happening: The company recently reported Q3 results.
• What ARC Document Solutions Does: ARC Document Solutions Inc is a global document solutions provider. The company's service offerings include managed print services (MPS), offsite services, archive and information management ( AIM), specialized color printing, Web-based document management applications, and equipment and supplies sales.

See more from Benzinga

• Click here for options trades from Benzinga
• 4 Stocks Insiders Are Buying
• 10 Biggest Price Target Changes For Tuesday

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.